Repeated central administration of selegiline attenuated morphine physical dependence in rat

Pharmacological Reports

Volumn 65, Issue 3, 2013, Pages 593-599

  Parvizpour, Alireza ^a   Charkhpour, Mohammad ^a   Habibi asl, Bohlool ^a   Shakhsi, Mobin ^a   Ghaderi, Majid ^b   Hassanzadeh, Kambiz ^c  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b ISLAMIC AZAD UNIVERSITY   (Iran)

^c KURDISTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Morphine; Physical dependence; Selegiline; Withdrawal symptoms

Indexed keywords

MORPHINE; NALOXONE; SELEGILINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR CHANGE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TREATMENT FAILURE; MALE; MORPHINE ADDICTION; NONHUMAN; RAT; WITHDRAWAL SYNDROME;

ANIMALS; INFUSIONS, INTRAVENTRICULAR; MALE; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; RATS; RATS, SPRAGUE-DAWLEY; RATS, WISTAR; SELEGILINE; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS;

EID: 84884479948     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71036-3     Document Type: Article

References (39)

1. Asl BH, Hassanzadeh K, Khezri E, Mohammadi S: Evaluation the effects of dextromethorphan and midazolam on morphine induced tolerance and dependence in mice. Pak J Biol Sci, 2008, 11, 1690-1695.
2. Charkhpour M, Nayebi AM: Evaluation of the role of 5-HT1A receptors in dorsal and median raphe nuclei on the morphine withdrawal syndrome in rat. Eur Neuropsychopharmacol, 2006, 16, S510-S511.
3. Dizgah IM, Karimian SM, Zarrindast MR, Sohanaki H: Attenuation of morphine withdrawal signs by a D1 receptor agonist in the locus coeruleus of rats. Neuroreport, 2005, 16, 1683-1686. (Pubitemid 41805803)
4. George TP, O'Malley SS: Current pharmacological treatments for nicotine dependence. Trends Pharmacol Sci, 2004, 25, 42-48. (Pubitemid 38081281)
5. Ghosh S, Patel AH, Cousins M, Grasing K: Different effects of opiate withdrawal on dopamine turnover, uptake, and release in the striatum and nucleus accumbens. Neurochem Res, 1998, 23, 875-885. (Pubitemid 28178161)
6. Goverdhan P, Sravanthi A, Mamatha T: Neuroprotective effects of meloxicam and selegiline in scopolamineinduced cognitive impairment and oxidative stress. Int J Alzheimers Dis, 2012, 974013.
7. Graham DG, Tiffany SM, Bell WR Jr, Gutknecht WF: Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol, 1978, 14, 644-653. (Pubitemid 8402470)
8. Habibi-Asl B, Alimohammadi B, Charkhpour M, Hassanzadeh K: Evaluation the effects of systemic administration of minocycline and riluzole on tolerance to morphine analgesic effect in rat. Pharma Sci (Journal of Faculty of Pharmacy, Tabriz University of Medical Sciences), 2009, 15, 205-212.
9. Habibi-Asl B, Hassanzadeh K: Effects of ketamine and midazolam on morphine induced dependence and tolerance in mice. DARU, 2004, 12, 101-105. (Pubitemid 39602007)
10. Habibi-Asl B, Hassanzadeh K, Charkhpour M: Central administration of minocycline and riluzole prevents morphine-induced tolerance in rats. Anesth Analg, 2009, 109, 936-942.
11. Habibi-Asl B, Hassanzadeh K, Moosazadeh S: Effects of ketamine and magnesium on morphine induced tolerance and dependence in mice. DARU, 2005, 13, 110-115. (Pubitemid 43160464)
12. Habibi-Asl B, Hassanzadeh K, Vafai H, Mohammadi S: Development of morphine induced tolerance and withdrawal symptoms is attenuated by lamotrigine and magnesium sulfate in mice. Pak J Biol Sci, 2009, 12, 798-803.
13. Halliwell B. Reactive oxygen species and the central nervous system: J Neurochem, 1992, 59, 1609-1623.
14. Hassanzadeh K, Habibi-Asl B, Farajnia S, Roshangar L: Minocycline prevents morphine-induced apoptosis in rat cerebral cortex and lumbar spinal cord: A possible mechanism for attenuating morphine tolerance. Neurotox Res, 2011, 19, 649-659.
15. Hassanzadeh K, Habibi-asl B, Roshangar L, Nemati M, Ansarin M, Farajnia S: Intracerebroventricular administration of riluzole prevents morphine-induced apoptosis in the lumbar region of the rat spinal cord. Pharmacol Rep, 2010, 62, 664-673.
16. Hassanzadeh K, Roshangar L, Habibi-asl B, Farajnia S, Izadpanah E, Nemati M, Arasteh M, Mohammadi S: Riluzole prevents morphine-induced apoptosis in rat cerebral cortex. Pharmacol Rep, 2011, 63, 697-707.
17. Heinonen EH, Anttila MI, Lammintausta RA: Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharmacol Ther, 1994, 56, 742-749. (Pubitemid 124006561)
18. Kashii S, Takahashi M, Mandai M, Shimizu H, Honda Y, Sasa M, Ujihara H et al.: Protective action of dopamine against glutamate neurotoxicity in the retina. Invest Ophthalmol Vis Sci, 1994, 35, 685-695. (Pubitemid 24078128)
19. Kitani K, Minami C, Isobe K, Maehara K, Kanai S, Ivy GO, Carrillo MC:Why (-) deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mech Ageing Dev, 2002, 123, 1087-1100. (Pubitemid 34603092)
20. Knoll J, Miklya I: Multiple, small dose administration of (-)deprenyl enhances catecholaminergic activity and diminishes serotoninergic activity in the brain and these effects are unrelated to MAO-B inhibition. Arch Int Pharmacodyn Ther, 1994, 328, 1-15. (Pubitemid 24353343)
21. Mizuta I, Ohta M, Ohta K, Nishimura M, Mizuta E, Hayashi K, Kuno S: Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem Biophys Res Commun, 2000, 279, 751-755. (Pubitemid 32042852)
22. Nayebi MA, Asadi M: Effect of buspirone on morphine withdrawal syndrome in mice. Pharma Sci (Journal of Faculty of Pharmacy, Tabriz University of Medical Sciences), 2009, 14, 229-235
23. Mytilineou C, Radcliffe P, Leonardi EK, Werner P, Olanow CW: L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro. J Neurochem, 1997, 68, 33-39. (Pubitemid 26427289)
24. Newton TF, Kalechstein A, Beckson M, Bartzokis G, Bridge TP, Ling W: Effects of selegiline pretreatment on response to experimental cocaine administration. Psychiatry Res, 1999, 87, 101-106. (Pubitemid 29494969)
25. Nowakowska E, Kus K, Chodera A, Rybakowski J: Investigating potential anxiolytic, antidepressant and memory enhancing activity of deprenyl. J Physiol Pharmacol, 2001, 52, 863-873. (Pubitemid 34042367)
26. Paterson IA, Tatton WG: Antiapoptotic actions of monoamine oxidase B inhibitors. Adv Pharmacol, 1998, 42, 312-315.
27. th edn., Academic Press, London, 1998.
28. Pereira CM, Oliveira CR: Glutamate toxicity on a PC12 cell line involves glutathione (GSH) depletion and oxidative stress. Free Radic Biol Med, 1997, 23, 637-647. (Pubitemid 27287347)
29. Rada P, Mark GP, Pothos E, Hoebel BG: Systemic morphine simultaneously decreases extracellular acetylcholine and increases dopamine in the nucleus accumbens of freely moving rats. Neuropharmacology, 1991, 30, 1133-1136.
30. Salo PT, Tatton WG: Deprenyl reduces the death of motoneurons caused by axotomy. J Neurosci Res, 1992, 31, 394-400.
31. Schapira AH, Olanow CW: Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. JAMA, 2004, 291, 358-364. (Pubitemid 38101609)
32. Schneider LS, Tariot PN, Goldstein B: Therapy with l-deprenyl (selegiline) and relation to abuse liability. Clin Pharmacol Ther, 1994, 56, 750-756. (Pubitemid 124006562)
33. Sepúlveda J, Astorga JG, Contreras E: Riluzole decreases the abstinence syndrome and physical dependence in morphine-dependent mice. Eur J Pharmacol, 1999, 379, 59-62. (Pubitemid 29492947)
34. Shimazu S, Katsuki H, Akaike A: Deprenyl rescues dopaminergic neurons in organotypic slice cultures of neonatal rat mesencephalon from N-methyl-D-aspartate toxicity. Eur J Pharmacol, 1999, 377, 29-34. (Pubitemid 29322754)
35. Shimazu S, Tanigawa A, Sato N, Yoneda F, Hayashi K, Knoll J: Enhancer substances: selegiline and R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP] enhance the neurotrophic factor synthesis on cultured mouse astrocytes. Life Sci, 2003, 72, 2785-2792. (Pubitemid 36385082)
36. Tjon Tien Ril HK, De Vries TJ, Wardeh G, Hogenboom F, Mulder AH, Schoffelmeer AN: Long-lasting reciprocal changes in striatal dopamine and acetylcholine release upon morphine withdrawal. Eur J Pharmacol, 1993, 235, 321-322. (Pubitemid 23130453)
37. Tokuyama S, Wakabayashi H, Ho IK: Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome. Eur J Pharmacol, 1996, 295, 123-129. (Pubitemid 26027131)
38. Trujillo KA: The neurobiology of opiate tolerance, dependence and sensitization: mechanisms of NMDA receptor-dependent synaptic plasticity. Neurotox Res, 2002, 4, 373-391.
39. Youdim MB, Finberg JP: Pharmacological actions of ldeprenyl (selegiline) and other selective monoamine oxidase B inhibitors. Clin Pharmacol Ther, 1994, 56, 725-733. (Pubitemid 124006559)